Nyxoah
Olivier Taelman is an experienced MedTech leader, joining Nyxoah in July 2019 as Chief Operating and Commercial Officer and subsequently being appointed as CEO in November 2019. Olivier spent 7 years in commercial healthcare at Eli Lilly and Sanofi Aventis leading specific Business Units. He spent 15 years within the field of neuromodulation at Medtronic, managing EMEA at Stryker NeuroVascular and serving a neuromodulation company Nevro where he was responsible for building the European business during the successful NASDAQ IPO.
This person is not in any offices
Nyxoah
Nyxoah is a medical device company focused on the development and commercialization of a hypoglossal nerve stimulation (HGNS) therapy.